Abstract
The philosophy of a British-based international company on adverse reaction monitoring and a response to the requirements of regulatory authorities is outlined. The protection of the patient is the objective of such monitoring and the methods by which this is achieved include active follow-up of reports, regular reviews of the data base, and communication with the medical profession.
Get full access to this article
View all access options for this article.